Associated Papers
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.
Arévalo NB et al.
Frontiers in Molecular Neuroscience, 2022
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T et al.
Translational Neurodegeneration, 2021
Molecular regulations and therapeutic targets of Gaucher disease.
Chen Y et al.
Cytokine & Growth Factor Reviews, 2018
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2016
Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease.
Dai M et al.
Plos One, 2016
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
Sun Y et al.
The Journal of Biological Chemistry, 2012
Animal models for Gaucher disease research.
Farfel-Becker T et al.
Disease Models & Mechanisms, 2011
Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.
Xu YH et al.
The American Journal of Pathology, 2003
Pathology of amino acid deficiency in rats; phenylalanine deficiency.
FERGUSON RL et al.
The American Journal of Pathology, 1948
Select a paper to view details